Evidence map›Paper›PMID 36262311›Full record

ArticleiScience2022

Ane Orrantia, Enrique Vázquez-De Luis, Gabirel Astarloa-Pando, Iñigo Terrén, Ainhoa Amarilla-Irusta, Diego Polanco-Alonso, Carmen González, Alasne Uranga, Tomás Carrascosa, Juan J Mateos-Mazón and 6 more

Abstract read
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ane OrrantiaImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Enrique Vázquez-De LuisGenomics Unit, Spanish National Center for Cardiovascular Research (CNIC), 28029 Madrid, Spain.
Gabirel Astarloa-PandoImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Iñigo TerrénImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Ainhoa Amarilla-IrustaImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Diego Polanco-AlonsoImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Carmen GonzálezBiodonostia Health Research Institute, Hematology and Hemotherapy Service, Donostia University Hospital, 20014 Donostia-San Sebastián, Spain.
Alasne UrangaBiodonostia Health Research Institute, Hematology and Hemotherapy Service, Donostia University Hospital, 20014 Donostia-San Sebastián, Spain.
Tomás CarrascosaHematological Cancer Group, Biocruces Bizkaia Health Research Institute, Hematology and Hemotherapy Service, Galdakao-Usansolo University Hospital, 48960 Galdakao, Spain.
Juan J Mateos-MazónHematological Cancer Group, Biocruces Bizkaia Health Research Institute, Hematology and Hemotherapy Service, Cruces University Hospital, 48903 Barakaldo, Spain.
Juan C García-RuizHematological Cancer Group, Biocruces Bizkaia Health Research Institute, Hematology and Hemotherapy Service, Cruces University Hospital, 48903 Barakaldo, Spain.
Sergio CallejasGenomics Unit, Spanish National Center for Cardiovascular Research (CNIC), 28029 Madrid, Spain.
Ana QuintasGenomics Unit, Spanish National Center for Cardiovascular Research (CNIC), 28029 Madrid, Spain.
Ana DopazoGenomics Unit, Spanish National Center for Cardiovascular Research (CNIC), 28029 Madrid, Spain.
Olatz ZenarruzabeitiaImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Francisco BorregoImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous hematopoietic stem cell transplantation (autoHSCT) is a treatment option for hematological disorders and pediatric solid tumors. After an autoHSCT, natural killer (NK) cells are the first lymphocyte subset returning to normal levels. To uncover global changes during NK cell reconstitution after autoHSCT, we performed RNA-sequencing on NK cells before and after autoHSCT. Results showed profound changes in the gene expression profile of NK cells immediately after autoHSCT. Several biological processes including cell cycle, DNA replication and the mevalonate pathway were enriched. Significantly, we observed that following autoHSCT, NK cells acquired a decidual-like gene expression profile, including the expression of CD9. By using multiparametric flow cytometry, we confirmed the expansion of NK cells expressing CD9 immediately after autoHSCT, which exhibited higher granzyme B and perforin expression levels than CD9

Indexed as

components of the immune systemHealth sciencesimmunologytranscriptomics

Identifiers

PMID36262311
PMCPMC9574507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.